RecruitingPhase 2NCT07431606

Duloxetine in Inflammatory Bowel Diseases

A Phase II Open-label Study of Duloxetine to Reduce Inflammatory Bowel Disease-Related Disability and Psychological Distress

Sponsor

University of Pennsylvania

Enrollment

32 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

Inflammatory Bowel Diseases

Summary

This open-label, prospective, single-arm pilot study investigates the use of duloxetine, a central neuromodulator, for improving psychological distress and functional impairment in adults with inflammatory bowel disease (IBD). The study focuses on patient-reported outcomes related to anxiety, depression, and IBD-related disability, aiming to assess feasibility, tolerability, and preliminary efficacy in modulating gut-brain axis symptoms and disease-related functional impairments in life

Eligibility

Min Age: 24 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Duloxetine for people with inflammatory bowel diseases. The study is currently recruiting participants at 1 location. People eligible for this study include aged 24 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.